GlassScriptPhysician profile
Robert Adam Arbuckle
NPI 1659663136
$580.26
in general payments reported to CMS, 2019-2025
11 companies · $182 in 2025
The $182 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.24 · 2020: $77.60 · 2021: $228 · 2022: $30.21 · 2023: $17.68 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $199.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $145.52 | 2021-2023 | Qulipta |
| Ucb, INC. | $136.54 | 2025 | Fintepla |
| Novartis Pharmaceuticals Corporation | $101.05 | 2019-2022 | |
| Eisai INC. | $45.69 | 2025 | |
| Allergan, INC. | $39.75 | 2020 | |
| Acorda Therapeutics, INC | $23.76 | 2019 | |
| Acadia Pharmaceuticals INC | $22.17 | 2020 | |
| Horizon Therapeutics Plc | $20.18 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $17.39 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.68 | 2020 | |
| Amgen INC. | $12.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Arbuckle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.